Altimmune (ALT) Cash & Equivalents (2016 - 2025)
Historic Cash & Equivalents for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $61.3 million.
- Altimmune's Cash & Equivalents rose 9443.46% to $61.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.3 million, marking a year-over-year increase of 9443.46%. This contributed to the annual value of $37.0 million for FY2024, which is 7264.83% down from last year.
- According to the latest figures from Q3 2025, Altimmune's Cash & Equivalents is $61.3 million, which was up 9443.46% from $183.1 million recorded in Q2 2025.
- Altimmune's Cash & Equivalents' 5-year high stood at $190.3 million during Q4 2021, with a 5-year trough of $31.5 million in Q3 2024.
- Moreover, its 5-year median value for Cash & Equivalents was $111.1 million (2022), whereas its average is $114.3 million.
- Per our database at Business Quant, Altimmune's Cash & Equivalents skyrocketed by 122603.99% in 2021 and then plummeted by 7264.83% in 2024.
- Altimmune's Cash & Equivalents (Quarter) stood at $190.3 million in 2021, then tumbled by 41.61% to $111.1 million in 2022, then rose by 21.62% to $135.2 million in 2023, then tumbled by 72.65% to $37.0 million in 2024, then surged by 65.76% to $61.3 million in 2025.
- Its Cash & Equivalents stands at $61.3 million for Q3 2025, versus $183.1 million for Q2 2025 and $49.1 million for Q1 2025.